These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30822450)

  • 41. A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus.
    Jiao YY; Fu YH; Yan YF; Hua Y; Ma Y; Zhang XJ; Song JD; Peng XL; Huang J; Hong T; He JS
    Antiviral Res; 2017 Aug; 144():57-69. PubMed ID: 28529001
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.
    Hwang HS; Kim KH; Lee Y; Lee YT; Ko EJ; Park S; Lee JS; Lee BC; Kwon YM; Moore ML; Kang SM
    Hum Vaccin Immunother; 2017 May; 13(5):1031-1039. PubMed ID: 28129031
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Non-propagating, recombinant vesicular stomatitis virus vectors encoding respiratory syncytial virus proteins generate potent humoral and cellular immunity against RSV and are protective in mice.
    Johnson JE; McNeil LK; Megati S; Witko SE; Roopchand VS; Obregon JH; Illenberger DM; Kotash CS; Nowak RM; Braunstein E; Yurgelonis I; Jansen KU; Kalyan NK; Sidhu MK
    Immunol Lett; 2013 Feb; 150(1-2):134-44. PubMed ID: 23261719
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A recombinant varicella vaccine harboring a respiratory syncytial virus gene induces humoral immunity.
    Murakami K; Matsuura M; Ota M; Gomi Y; Yamanishi K; Mori Y
    Vaccine; 2015 Nov; 33(45):6085-92. PubMed ID: 26116253
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nanobodies® specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion.
    Schepens B; Ibañez LI; De Baets S; Hultberg A; Bogaert P; De Bleser P; Vervalle F; Verrips T; Melero J; Vandevelde W; Vanlandschoot P; Saelens X
    J Infect Dis; 2011 Dec; 204(11):1692-701. PubMed ID: 21998474
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Orally administered adenoviral-based vaccine induces respiratory mucosal memory and protection against RSV infection in cotton rats.
    Joyce C; Scallan CD; Mateo R; Belshe RB; Tucker SN; Moore AC
    Vaccine; 2018 Jul; 36(29):4265-4277. PubMed ID: 29895499
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats.
    Smith G; Raghunandan R; Wu Y; Liu Y; Massare M; Nathan M; Zhou B; Lu H; Boddapati S; Li J; Flyer D; Glenn G
    PLoS One; 2012; 7(11):e50852. PubMed ID: 23226404
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Stability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein.
    Flynn JA; Durr E; Swoyer R; Cejas PJ; Horton MS; Galli JD; Cosmi SA; Espeseth AS; Bett AJ; Zhang L
    PLoS One; 2016; 11(10):e0164789. PubMed ID: 27764150
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discovery and Characterization of Phage Display-Derived Human Monoclonal Antibodies against RSV F Glycoprotein.
    Chen Z; Zhang L; Tang A; Callahan C; Pristatsky P; Swoyer R; Cejas P; Nahas D; Galli J; Cosmi S; DiStefano D; Hoang VM; Bett A; Casimiro D; Vora KA
    PLoS One; 2016; 11(6):e0156798. PubMed ID: 27258388
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel antigens for RSV vaccines.
    Graham BS; Modjarrad K; McLellan JS
    Curr Opin Immunol; 2015 Aug; 35():30-8. PubMed ID: 26070108
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Epicutaneous immunization using synthetic virus-like particles efficiently boosts protective immunity to respiratory syncytial virus.
    Hervé PL; Dhelft V; Zuniga A; Ghasparian A; Rassek O; Yim KC; Donne N; Lambert PH; Benhamou PH; Sampson HA; Mondoulet L
    Vaccine; 2021 Jul; 39(32):4555-4563. PubMed ID: 34154864
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Soluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles.
    Lee Y; Lee YT; Ko EJ; Kim KH; Hwang HS; Park S; Kwon YM; Kang SM
    Hum Vaccin Immunother; 2017 Nov; 13(11):2594-2605. PubMed ID: 28854003
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Research Progress in the F Gene and Protein of the Respiratory Syncytial Virus].
    Zhang F; Xie Z
    Bing Du Xue Bao; 2015 Mar; 31(2):201-6. PubMed ID: 26164949
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Single mucosal immunization of recombinant adenovirus-based vaccine expressing F1 protein fragment induces protective mucosal immunity against respiratory syncytial virus infection.
    Kim S; Jang JE; Yu JR; Chang J
    Vaccine; 2010 May; 28(22):3801-8. PubMed ID: 20362203
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Structure basis of neutralization by a novel site II/IV antibody against respiratory syncytial virus fusion protein.
    Xie Q; Wang Z; Ni F; Chen X; Ma J; Patel N; Lu H; Liu Y; Tian JH; Flyer D; Massare MJ; Ellingsworth L; Glenn G; Smith G; Wang Q
    PLoS One; 2019; 14(2):e0210749. PubMed ID: 30730999
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunogenicity and efficacy of recombinant RSV-F vaccine in a mouse model.
    Singh SR; Dennis VA; Carter CL; Pillai SR; Jefferson A; Sahi SV; Moore EG
    Vaccine; 2007 Aug; 25(33):6211-23. PubMed ID: 17629376
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recombinant influenza virus carrying the respiratory syncytial virus (RSV) F85-93 CTL epitope reduces RSV replication in mice.
    De Baets S; Schepens B; Sedeyn K; Schotsaert M; Roose K; Bogaert P; Fiers W; Saelens X
    J Virol; 2013 Mar; 87(6):3314-23. PubMed ID: 23302879
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of a respiratory syncytial virus vaccine candidate in a maternal immunization model.
    Blanco JCG; Pletneva LM; McGinnes-Cullen L; Otoa RO; Patel MC; Fernando LR; Boukhvalova MS; Morrison TG
    Nat Commun; 2018 May; 9(1):1904. PubMed ID: 29765035
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques.
    Elliott MB; Chen T; Terio NB; Chong SY; Abdullah R; Luckay A; Egan MA; Boutilier LA; Melville K; Lerch RA; Long D; Eldridge JH; Parks CL; Udem SA; Hancock GE
    Vaccine; 2007 Oct; 25(41):7132-44. PubMed ID: 17850933
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats.
    Kamphuis T; Shafique M; Meijerhof T; Stegmann T; Wilschut J; de Haan A
    Vaccine; 2013 Apr; 31(17):2169-76. PubMed ID: 23499594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.